Review of multidrug-resistant and extensively drug-resistant TB: Global perspectives with a focus on sub-Saharan Africa

Tropical Medicine and International Health

Volumn 15, Issue 9, 2010, Pages 1052-1066

  Migliori, Giovanni Battista ^a   Dheda, Keertan ^b,c   Centis, Rosella ^a   Mwaba, Peter ^d   Bates, Matthew ^c,d   O'Grady, Justin ^c,d   Hoelscher, Michael ^e   Zumla, Alimuddin ^c,d  

^a IRCCS   (Italy)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY TEACHING HOSPITAL   (Zambia)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

drugs; epidemiology; MDR TB; microbiology; treatment; tuberculosis; XDR TB

Indexed keywords

2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CYCLOSERINE; DIARYLQUINOLINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; LL 3858; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; SUDOTERB; TERIZIDONE; THIOACETAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DISEASE CONTROL; DISEASE TREATMENT; DRUG RESISTANCE; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; MICROBIOLOGY; MORTALITY; PUBLIC HEALTH; TUBERCULOSIS;

AFRICA; ALR GENE; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; EMBB GENE; ETHR GENE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GYRA GENE; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; IMMUNOTHERAPY; INFECTION PREVENTION; INHS GENE; INSOMNIA; LACTIC ACIDOSIS; LIVER TOXICITY; LUNG RESECTION; MIXED INFECTION; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATOR GENE; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; OPTIC NEURITIS; OTHA GENE; OTOTOXICITY; PANCREATITIS; PARESTHESIA; PATIENT CARE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PNCA GENE; PREVALENCE; PSYCHOSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; RRS GENE; SEIZURE; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS CONTROL;

AFRICA SOUTH OF THE SAHARA; ANTITUBERCULAR AGENTS; ASIA; EUROPE, EASTERN; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HIV INFECTIONS; HUMANS; ISONIAZID; RIFAMPIN; SOUTH AMERICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ASIA; EASTERN EUROPE; SAHARA; SOUTH AMERICA;

EID: 77955366768     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2010.02581.x     Document Type: Article

References (74)

1. Abdool Karim SS, Churchyard GJ, Abdool Karim Q Lawn SD (2009) HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 374 (9693 921 933.
2. Amor Y, Nemser B, Singh A, Sankin A Schluger N (2008) Underreported threat of multidrug-resistant tuberculosis in Africa. Emerging Infectious Diseases 14, 1345 1352.
3. Balabanova Y, Ruddy M, Hubb J et al. (2005) Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. European Journal of Clinical Microbiology and Infectious Diseases 24, 136 139.
4. Caminero JA (2008) Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Programme implementation. The International Journal of Tuberculosis and Lung Disease 12, 869 877.
5. Centers for Disease Control and Prevention (2006) Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide. Morbidity and Mortality Weekly Report 55, 301 305.
6. Chan ED, Laurel V, Strand MJ et al. (2004) Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine 169, 1103 1109.
7. Chiang C-Y, Yu M-C, Bai K-J, Lin T-P Lee Y-C (2001) Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan. The International Journal of Tuberculosis and Lung Disease 5, 272 277.
8. Chiang C-Y, Enarson DA, Yu M-C et al. (2006) Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. European Respiratory Journal 28, 980 985.
9. Chiang C-Y, Caminero JA Enarson DA (2009) Reporting on multidrug-resistant tuberculosis: a proposed definition for the treatment outcome 'failed". The International Journal of Tuberculosis and Lung Disease 13, 548 550.
10. Chirenda J, Menzies H, Moalosi G et al. (2009) The trend of resistance to anti-tuberculosis drugs in Botswana: results from the 4th national anti-tuberculosis drug resistance survey. 40th Union World Conference on Lung Health. Int J TB Lung Dis, Cancun, Mexico.
11. Churchyard G, Kaplan G, Fallows D, Wallis RS, Onyebujoh P Rook GA (2009) Advances in immunotherapy for Tuberculosis treatment. Clinics in Chest Medicine. Tuberculosis volume, Eds A. Zumla and S. Schaaf. 30 (4 769 796.
12. Dheda K, Shean K, Zumla A et al. (2010) Early treatment outcomes of extensively drug-resistant tuberculosis in South Africa are poor regardless of HIV status. The Lancet 375, 1798 1807.
13. Dravniece G, Cain KP, Holtz TH, Riekstina V, Leimane V Zaleskis R (2009) Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. European Respiratory Journal 34, 180 183.
14. Dubrovina I, Miskinis K, Lyepshina S et al. (2008) Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics? The International Journal of Tuberculosis and Lung Disease 12 (7 756 762.
15. Elliott AM, Halwiindi B, Hayes RJ et al. (1993) The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. Journal of Tropical Medicine and Hygiene 96, 1 11.
16. Espinal MA (2003) Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. The International Journal of Tuberculosis and Lung Disease 7, 607 608.
17. Espinal MA, Kim SJ, Suarez PG et al. (2000) Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 283, 2537 2545.
18. Espinal MA, Laszlo A, Simonsen L et al. (2001) Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. New England Journal of Medicine 344 (17 1294 1303.
19. Flament-Saillour M, Robert J, Jarlier V Grosset J (1999) Outcome of multi-drug-resistant tuberculosis in France. A nationwide case-control study. American Journal of Respiratory and Critical Care Medicine 160, 587 593.
20. Gandhi NR, Moll A, Sturm AW et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis in a rural area of South Africa. The Lancet 368, 1575 1580.
21. Gandhi NR, Shah NS, Andrews JR et al. (2010a) HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Tugela Ferry Care and Research (TF CARES) Collaboration. American Journal of Respiratory and Critical Care Medicine 181 (1 80 86.
22. Gandhi N, Nunn P, Dheda K et al. (2010b) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. The Lancet 375 (9728 1830 1843.
23. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L Horsburgh CR Jr. (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. New England Journal of Medicine 328, 527 532.
24. Grobusch MP (2010) Drug-resistant and extensively drug-resistant tuberculosis in southern Africa. Current Opinion in Pulmonary Medicine 16 (3 180 185.
25. Habeenzu C, Mitarai S, Lubasi D et al. (2007) Tuberculosis and multidrug resistance in Zambian prisons, 2000-2001. The International Journal of Tuberculosis and Lung Disease 11, 1216 1220.
26. Hoek KG, Gey van Pittius NC, Moolman-Smook H et al. (2008) Fluorometric assay for testing rifampin susceptibility of Mycobacterium tuberculosis complex. Journal of Clinical Microbiology 46, 1369 1373.
27. Holtz TH Cegielski JP (2007) Origin of the term XDR-TB. European Respiratory Journal 30, 396.
28. Holtz TH, Riekstina V, Zarovska E et al. (2005) XDR-TB: extreme drug-resistance and treatment outcome under DOTS-Plus, Latvia, 2000-2002. The International Journal of Tuberculosis and Lung Disease 9 (Suppl. 1 S258.
29. Iseman MD, Madsen L, Goble M Pomerantz M (1990) Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. The American Review of Respiratory Disease 141, 623 625.
30. Johnson R, Streicher E, Louw GE et al. (2009) Drug resistance in Mycobacterium tuberculosis. Current Issues in Molecular Biology 8, 97 112.
31. Kehinde AO, Obaseki FA, Ishola OC Ibrahim KD (2007) Multidrug resistance to Mycobacterium tuberculosis in a tertiary hospital. Journal of the National Medical Association 99, 1185 1189.
32. Kim HJ, Hong YP, Kim SJ, Lew WJ Lee EG (2001) Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. The International Journal of Tuberculosis and Lung Disease 5, 1129 1136.
33. Kingkaew N, Sangtong B, Amnuaiphon W et al. (2009) HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death. International Journal of Infectious Diseases 13 (6 722 729.
34. Korenromp EL, Scano F, Williams BG et al. (2003) Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clinical Infectious Diseases 37, 101 112.
35. Kranzer K, Bekker LG, Van Schaik N et al. (2010) Community health care workers in South Africa are at increased risk for tuberculosis. South African Medical Journal 100 (4 224 226. No abstract available.
36. Lalloo UG Pillay S (2008) Managing tuberculosis and HIV in sub-Sahara Africa. Current HIV/AIDS Reports 5 (3 132 139. Review.
37. Laserson KF, Thorpe LE, Leimane V et al. (2005) Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease 9, 640 645.
38. Lienhardt C, Vernon A Raviglione MC (2010) New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine 16 (3 186 193.
39. Ma Z, Lienhardt C, McIlleron H, Nunn AJ Wang X (2010) Global tuberculosis drug development pipeline: the need and the reality. The Lancet Epub ahead of print A
40. Panaiotov S, Portaels F, Hoffner S, Palomino JC Angeby K (2008) The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy 62, 56 64.
41. Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E Raviglion M (2007) Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Review of Anti-infective Therapy 5 (5 857 871.
42. Meskel DW, Abate G, Lakew M, Goshu S Aseffa A (2008) Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital. Ethiopian Medical Journal 46, 219 225.
43. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M Raviglione MC (2002) Frequency of recurrence among MDR-TB cases 'successfully' treated with standardised short-course chemotherapy. The International Journal of Tuberculosis and Lung Disease 6, 858 864.
44. Migliori GB, Besozzi G, Girardi E et al. (2007a) Clinical and operational value of the extensively drug-resistant tuberculosis definition. European Respiratory Journal 30 (4 623 626.
45. Migliori GB, Ortmann J, Girardi E et al. (2007b) Extensively drug-resistant tuberculosis, Italy and Germany. Emerging Infectious Diseases 13 (5 780 782.
46. Migliori GB, Richardson MD, Sotgiu G Lange C (2009) Multidrug-resistant and extensively drug-resistant tuberculosis in the West, Europe and United States: epidemiology, surveillance, and control. Clinics in Chest Medicine 30, 637 665.
47. Migliori GB, Centis R, Lange C, Richardson MD Sotgiu G (2010) Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. Current Opinion in Pulmonary Medicine 16 (3 171 179.
48. Moore DA, Evans CA, Gilman RH et al. (2006) Microscopic-observation drug-susceptibility assay for the diagnosis of TB. New England Journal of Medicine 355, 1539 1550.
49. Motus IY, Skorniakov SN, Sokolov VA et al. (2006) Reviving an old idea: can artificial pneumothorax play a role in the modern management of tuberculosis? The International Journal of Tuberculosis and Lung Disease 10, 571 577.
50. O'Donnell MR, Padayatchi N, Master I, Osburn G Horsburgh CR (2009) Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. The International Journal of Tuberculosis and Lung Disease 13 (7 855 861.
51. Pablos-Méndez A, Raviglione MC, Laszlo A et al. (1998) Global surveillance for antituberculosis-drug resistance, 1994-1997. The New England Journal of Medicine 338 (23 1641 1649.
52. Pai M, Kalantri S Dheda K (2006) New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Review of Molecular Diagnostics 6, 423 432. (Pubitemid 44174346)
53. Park SK, Kim CT Song SD (1998) Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. The International Journal of Tuberculosis and Lung Disease 2, 877 884.
54. Pietzka AT, Indra A, Stoger A et al. (2009) Rapid identification of multidrug-resistant Mycobacterium tuberculosis isolates by rpoB gene scanning using high-resolution melting curve PCR analysis. Journal of Antimicrobial Chemotherapy 63, 1121 1127.
55. Pillay M Sturm AW (2010) Nosocomial transmission of the F15/LAM4/KZN genotype of Mycobacterium tuberculosis in patients on tuberculosis treatment. The International Journal of Tuberculosis and Lung Disease 14 (2 223 230.
56. Quy HTW, Lan NTN, Borgdorff MW et al. (2003) Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? The International Journal of Tuberculosis and Lung Disease 7, 631 636.
57. Saravia JC, Appleton SC, Rich ML, Sarria M, Bayona J Becerra MC (2005) Retreatment strategies when first-line tuberculosis therapy fails. The International Journal of Tuberculosis and Lung Disease 9, 421 429.
58. Schaaf S Dheda K (2009) Multidrug and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children. Clinics in Chest Medicine Eds A. Zumla and S. Schaaf. Tuberculosis volume 300 (4 667 683.
59. Schaaf S Zumla A Eds (2009) Tuberculosis - A Comprehensive Clinical Reference, 107 Chapters. Publishers Elsevier Saunders, UK.
60. Shah NS, Wright A, Drobniewski F et al. (2005) Extreme drug resistance in tuberculosis ("XDR-TB"): global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. The International Journal of Tuberculosis and Lung Disease 9 (Suppl 1 S77.
61. Somocurcio JG, Sotomayor A, Shin S et al. (2007) Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax 62, 416 421.
62. Sonnenberg P, Murray J, Glynn JR et al. (2001) HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358, 1687 1693.
63. Sotgiu G, Ferrara G, Matteelli A et al. (2009) Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal 33 (4 871 881.
64. TB Alliance (2010) Global alliance website http://www.tballinace.org/ cptr/ (accessed 26 May 2010).
65. Torun T, Tahaoglu K, Ozmen I et al. (2007) The role of surgery and fluoroquinolones in the treatment of multidrug-reistant tuberculosis. The International Journal of Tuberculosis and Lung Disease 11, 979 985.
66. Umubyeyi AN, Vandebriel G, Gasana M et al. (2007) Results of a national survey on drug resistance among pulmonary tuberculosis patients in Rwanda. The International Journal of Tuberculosis and Lung Disease 11, 189 194.
67. Wallis RS, Pai M, Menzies D et al. (2010) Biomarkers and diagnostics for tuberculosis: progress, current needs and translation into practice. The Lancet 375, 1920 1937.
68. WHO (2009) WHO Policy on TB Infection Control in Health-care Settings, Congregate Settings and Households. World Health Organization, Geneva.
69. WHO (2010) WHO Report 2010: Multidrug and Extensively Drug-resistant TB (MDR-/XDR-TB). 2010 Global Report on Surveillance and Response. WHO, Geneva. WHO/HTM/TB/2010.3.
70. WHO and IUATLD (2008) Anti-tuberculosis Drug Resistance in the World: Fourth Global Report. World Health Organization, Geneva.
71. World Health Organization (2007) The global MDR-TB & XDR-TB response plan 2007-2008. World Health Organization Document 2007;WHO/HTM/STB/2007.2007. 387:1-s51.
72. Wright A, Zignol M, Van Deun A et al. for the Global Project on Anti-Tuberculosis Drug Resistance Surveillance (2009a) Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373 (9678 1861 1873.
73. Wright A, Zignol M, Van Deun A et al. (2009b) Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373, 1861 1873.
74. Zumla A Schaaf S, Eds (2009) Clinics in Chest Medicine. Tuberculosis Volume, December 2009. Publishers Elsevier Saunders, Philadelphia, USA, p. 13.